Español 
English
Development and validation of a mass spectrometric method to determine the identity of rituximab based on its microheterogeneity profile. IN PRESS
Artículos Relacionados
-
UDIBI
Fecha de publicación: 20 Septiembre 2019 Validation of a Cell Proliferation Assay to Assess the Potency of a Dialyzable...
-
UDIBI
Mycobacterium tuberculosis Catalase Inhibits the Formation of Mast Cell Extracellular Traps. VER MÁS
-
UDIBI
Validation of a cell proliferation assay to assess the potency of a Dialyzable Leucocyte Extract intended for batch release....
-
UDIBI
Fecha de publicación: 10 de abril de 2019 CD80 Expression Correlates with IL-6 Production in THP-1-Like Macrophages Costimulated with...
-
UDIBI
Sequencing Analysis and Identification of the Primary Peptide Component of the Dialyzable Leukocyte Extract “Transferon Oral”: The Starting Point...
-
UDIBI
Fecha de publicación: Marzo 2021 Poor survival in COVID-19 associated with Lymphopenia and Higher Neutrophile-Lymphocyte ratio Ver más
-
UDIBI
Efficacy, Pharmacokinetics, and Toxicity Profiles of Broad Anti-SARS-CoV-2 Neutralizing Antibody. VER MÁS
-
UDIBI
Fecha de publicación: 20 Septiembre 2019 Utilization of naproxen by Amycolatopsis sp. Poz 14 and detectionof the enzymes involved...
